Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abacavir/Lamivudine in Systemic Lupus Erythematosus
NCT06356740Phase 2Not yet recruiting
- Sponsor
- Hospices Civils de Lyon
- Start
- Sep 2024
- Primary completion
- Nov 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of abacavir, lamivudine in systemic lupus erythematosus (SLE), sponsored by Hospices Civils de Lyon. Planned start Sep 2024; status: not yet recruiting.
02
Drugs
abacavirlamivudine
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT06356740.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06356740.